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Women with polycystic ovary syndrome (PCOS), one of the
commonest endocrine conditions in the human, are more likely
than other women to have increased blood pressure, endothelial
dysfunction, reduced arterial compliance, central obesity, dyslipidae-
mia, low grade chronic inﬂammation, and increased endothelin-1 and
homocysteine [1]. A recent meta-analysis found an increased
incidence of cardiovascular events in women with PCOS, but did not
distinguish between coronary heart disease and stroke and did not
consider fatal and non-fatal events separately [2]. The present meta-
analysis aimed to quantify the risk of non-fatal stroke and coronary
heart disease as separate disease events in women with PCOS
compared to healthy women.
The Mantel–Haenszel method was used, with a random effects
model in most cases, to generate an odds ratio (OR) for all included
studies combined. Results were considered statistically signiﬁcant
where the probability value was below the 0.05 threshold. Review
Manager statistical software, version 5.1, was used to analyse data.
Heterogeneity was assessed using I2 and chi square statistics.
Nine studies met the inclusion criteria (see list of included studies
here [www.ijc.com/references). Women with PCOS were at increased
risk of non-fatal stroke and non-fatal CHD but the odds ratios did not
reach statistical signiﬁcance (OR, 1.61; 95% CI, 0.82–3.15; P = 0.17 and
OR, 1.63; 95% CI, 0.96–2.78; P = 0.07, respectively). In the ﬁve studies
where the average age was more than 45 years old, the risk in PCOS
was signiﬁcantly increased for non-fatal stroke (OR, 1.94; 95%
conﬁdence interval, 1.19–3.17) and non-signiﬁcantly increased in
the six studies of CHD (OR, 1.70; 95% conﬁdence interval, 0.92–3.11)
(Fig. 1).
For the three studies where the BMI was similar and the mean age
was over 45 in the groups the risk was non-signiﬁcantly increased for
womenwith PCOS for stroke (OR, 1.67; 95% conﬁdence interval, 0.70–
4.02) and for the three studies of CHD (OR, 2.04; 95% conﬁdence
interval, 0.60–6.97).
The Newcastle–Ottawa scale suggests that the methodological
quality of the included studies was moderate. Funnel plots found that
although publication bias cannot be ruled out, the asymmetry
observed may be due to the relatively young age of the patients in
one study.
Women with PCOS appear to be at increased risk of non-fatal
stroke and possibly CHD. Although this study was not designed to
investigate mechanism, the higher blood pressure and atherogenic
lipid proﬁle in women with PCOS may be contributory. In any case,
clinicians and policymakers might focus on screening women with
PCOS as soon as it is diagnosed, and focus on applying preventative
measures, such as lifestyle interventions, appropriate to reducing the
risk of stroke.
Whilst the results of the present meta-analysis did not provide
evidence of increased risk of CVD in PCOS entirely independent of BMI,
evidence of cardiovascular risk in leanwomenwith PCOS [3] supports
the hypothesis of the potential for an independent role of PCOS in
CVD, perhaps due to the abdominal obesity in PCOS [5]. Future studies
of PCOS should measure waist circumference in order to assess
abdominal obesity. Furthermore, many women with PCOS receive
treatments (the oral contraceptive pill, antiandrogens, insulin sensi-
tizers or laparoscopic ovarian diathermy) which are likely to modify
the risk of later cardiovascular events [4]. Future studies should
therefore also assess the impact of these interventions on cardiovas-
cular risk in women with PCOS.
These ﬁndings have important implications for disease prevention
and screening in women. At present, weight management, changes in
dietary composition and exercise should be the primary interventions,
although pharmacologic treatment of hypertension, dyslipidaemia or
insulin resistancemay be requiredwhere lifestyle modiﬁcation proves
ineffective.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijcard.2014.06.079.
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Hypertension (HTN) is a primary risk factor for cardiovascular
disease. The costs following cardiovascular events in hypertensive
patients are reportedly substantial [1,2]. The estimated direct and
indirect costs of HTN among Americans in 2007 totaled $66.4 billion,
making HTN the secondmost costly cardiovascular-related disorder [1].
Lloyd et al. estimated that UK patients with failure to achieve blood
pressure targets experience 58,000 unnecessary major cardiovascular
events annually, at a cost of £97.2 million [2]. These studies have
emphasized the disease burden of uncontrolled HTN, causing consider-
able increases in medical expenditure and in comorbid disease.
In South Korea, the total prevalence rate of HTN in people aged
30 years and over was 26.9% in 2010 [3]. During the 4-year period
from 2005 through 2009, HTN therapy costs increased by 64.3% from
$1.4 billion to $2.3 billion [4]. Moreover, medical expenditure to treat
(primary) HTN and other hypertensive diseases is an estimated
2.5 trillion KRW [4]. Given that the proportion of HTN-associated
comorbidities is estimated to be 50% [5] and given that the South
Korean population is aging rapidly, the future cost burden of HTN and
its comorbid conditions will be profound.
In this study, we calculated the direct medical costs of treating HTN
and associated comorbidities in South Korea.
This study analyzed data from the 2009 South Korean Health
Insurance Review and Assessment Service-National Patients Sample
(HIRA-NPS) data. The HIRA database contains reimbursement records
from all medical facilities, including both hospitalized cases and
outpatient clinic cases, in South Korea. The 2009 HIRA-NPS contains
approximately 700,000 in patients (13% of total in patients) and
approximately 400,000 outpatients (1% of total outpatients) extracted
Fig. 1. Forest plot comparing risk of non-fatal stroke in women with PCOS compared to controls in the older age group (mean N 45 years) (above) and forest plot comparing risk of
non-fatal CHD in women with PCOS compared to controls in the older age group (mean N 45 years) (below).
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